A Study of H3B-6545 in Combination With Palbociclib in Women With Advanced or Metastatic Estrogen Receptor-Positive Human Epidermal Growth Factor Receptor-2 (HER2)-Negative Breast Cancer
Conditions: Receptors, Estrogen; Genes, Erbb-2; Breast Neoplasms Interventions: Drug: Palbociclib (75, 100, 125 milligram [mg]); Drug: H3B-6545 (300, 450 mg) Sponsors: H3 Biomedicine Inc.; Eisai Inc. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials